Keenova Therapeutics plc Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 27, 2024	FY2023 1 months to Dec 29, 2023	FY2022 6 months to Dec 30, 2022	FY2021 12 months to Dec 31, 2021
Restricted Cash and Investments, Current
Restricted Cash and Investments, Noncurrent
Cash Flows From Operating Activities - Continuing Operations:
Net income (loss)
(Loss) income from continuing operations
Adjustments to reconcile net cash from operating activities:
Depreciation and amortization
Share-based compensation
Deferred income taxes
Non-cash impairment charges
Loss (gain) on divestiture (Note 6)
Loss (gain) on debt extinguishment (Note 15)
Inventory step-up amortization from acquisitions
Inventory provisions
Fair value adjustment in contingent consideration liabilities
Reorganization items, net
Non-cash (amortization) accretion expense
Other non-cash items
Accretion Expense
Changes in assets and liabilities:
Accounts receivable, net
Inventories
Accounts payable
Accrued consulting fees
Income taxes
Opioid-Related Litigation Settlement liability
Acthar Gel-Related Litigation Settlement liability
Medicaid lawsuit
Payment of claims
Other
Net cash from operating activities
Net cash provided by (used in) operating activities - continuing operations
Cash Flows From Investing Activities - Continuing Operations:
Capital expenditures
Receipts of unrestricted cash, net of payments related to the Business Combination (Note 5)
Receipts of restricted cash related to the Business Combination (Note 5)
(Payments) proceeds from divestiture, net of divested cash (Note 6)
Proceeds from Sale of Restricted Investments
Other
Net cash from investing activities
Net cash provided by (used in) investing activities - continuing operations
Cash Flows From Financing Activities - Continuing Operations:
Repayment of external debt
Divested cash from spin of Par Health
Makewhole premium (Note 15)
Debt financing costs
Proceeds from exercise of share options
Repurchase of shares
Payments for contingent value rights award cancellation
Other
Net cash (used in) provided by financing activities - continuing operations

Discontinued Operations:
Net cash provided by (used in) operating activities - discontinued operations
Net cash used in investing activities - discontinued operations
Net cash provided by financing activities - discontinued operations
Net cash provided by (used in) discontinued operations
Effect of currency rate changes on cash
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Less: Cash and cash equivalents at end of period - discontinued operations
Less: Restricted cash included in other long-term assets at end of period - discontinued operations
Cash, cash equivalents and restricted cash at end of period - continuing operations
Cash and cash equivalents at end of period - continuing operations
Restricted cash included in prepaid expenses and other assets at end of period - continuing operations
Restricted cash included in other long-term assets at end of period - continuing operations
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest, net
Cash paid (received) for income taxes, net
Cash and cash equivalents at end of period
Restricted cash included in prepaid expenses and other assets at end of period (Note 21)
Restricted cash included in other long-term assets at end of period (Note 21)

Comments